How do you approach treatment of patients with metastatic HR+ breast cancer with detection of ESR1 mutation after initiation of an AI and CDK4/6 Inhibitor?

In PADA-1 (SABCS 2021), the development of an ESR1 mutation, regardless of progression on scans, followed by the continuation of palbociclib but changing to fulvestrant, was associated with a PFS of 11.9 m. If one waited until clinical progression, then treated with fulvestrant and palbociclib, the ...

For patients with metastatic hormone receptor-positive (HR+) breast cancer (MBC) who develop an ESR1 mutation (ESR1mut) after initiation of an aromatase inhibitor (AI) and CDK4/6 inhibitor, there are several factors to consider. It is important to understand the full spectrum of potential biomarkers...

Based on the results of the PADA-1 trial that showed longer composite progression free survival in patients who switched an aromatase inhibitor to fulvestrant upon detection of ESR1 mutation in the circulating tumor DNA (as compared to patients with detectable ESR1 mutation who waited until radiogra...